ROIV
Roivant SciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
Current thesis
Successful pivotal readouts or favorable regulatory outcomes derisk lead programs and trigger re-rating toward premium multiples and analyst highs.
Posture
Mixed
Lead driver
Momentum
What changed
3 setup hits (3d) with net bullish as of 2026-06-12.
What can break
Equity dilution / financing risk
Momentum
75
Value
41
Sentiment
33
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $25.37 · Bull $32.98 · Bear $20.30
Data freshness
Prices
As of 2026-06-11
Fundamentals
As of 2026-06-11 • Vendor: Data Vendor v1
Scores
As of 2026-06-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-11
Investment thesis
As of 2026-06-11
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $33.10
Why
Momentum75 · Δ7d -2.1
Value41 · Δ7d -0.1
Sentiment33 · Δ7d -3.3
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
75
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.1
Δ21d
-4.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
33
33% active weight
Current posture
7d trendSoftening
Δ7d
-3.3
Δ21d
+11.5
Why this grade
Composite grade C. Momentum 75.1 / Value 41.0 / Sentiment 33.1
Fundamentals (TTM)As of 2026-06-11
Fundamentals (TTM)
As of 2026-06-11
Market Cap
$21.38B
Beta
1.23
Shares Out
695.49M
P/E (TTM) · Derived
-128.1
P/S (TTM)
728.71
P/FCF (TTM) · Derived
-27.36
Rev YoY
-64.9%
EPS YoY
+34.5%
Gross Margin
+96.4%
Op Margin
-5644.1%
Net Debt
-
Current Ratio
33.70
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology